CCM
AMED

Cloverdale Capital Management’s Amedisys AMED Stock Holding History

Cloverdale Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,050
Closed -$2.99M – 3
2020
Q2 		$2.99M Buy
+15,050
New +$2.81M 2.22% 24

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cloverdale Capital Management's AMED Position: Q3 2020 in Review

Cloverdale Capital Management sold out of Amedisys (AMED) in Q3 2020, closing a stake of 15,050 shares — an estimated $2.99M sold.

Cloverdale Capital Management first reported a position in AMED in Q2 2020 and held it in 1 quarter. The position peaked at $2.99M in Q2 2020. 397 funds tracked by Wall St. Rank hold AMED as of Q3 2020.

  • Cloverdale Capital Management reported no remaining Amedisys position as of Q3 2020 after selling out during the quarter.
  • Cloverdale Capital Management sold 15,050 Amedisys shares in Q3 2020, an estimated $2.99M.
  • Cloverdale Capital Management first reported a position in Amedisys in Q2 2020 and held it in 1 quarter.
  • Cloverdale Capital Management's Amedisys position peaked at $2.99M in Q2 2020.
  • 397 funds tracked by Wall St. Rank held Amedisys as of Q3 2020.

Based on Cloverdale Capital Management's 13F filing for Q3 2020.